Výsledky vyhledávání

Integrated acidity and rabeprazole pharmacology

Autor: J D, Gardner, C, Perdomo, S, Sloan, W F, Hahne, J A, Barth, S, Rodriguez-Stanley, M, Robinson

Publikováno v: Alimentary pharmacologytherapeutics. 16(3)

Integrated gastric and oesophageal acidity can be calculated from measurements of gastric and oesophageal pH and used to quantify gastric and oesophageal acidity over time. Rabeprazole is a new proton pump inhibitor that is effective in treating gast

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::e6511de09159589927ed24c9a25e3eee
https://pubmed.ncbi.nlm.nih.gov/11876698

Zobrazit plný text záznamu

Plný text ve formátu HTML

Dolasetron for the prevention of postoperative nausea and vomiting following outpatient surgery with general anaesthesia: a randomized, placebo-controlled study. The Dolasetron PONV Prevention Study Group

Autor: B K, Philip, M H, Pearman, A L, Kovac, J E, Chelly, B V, Wetchler, R, McKenzie, T G, Monk, M, Dershwitz, M, Mingus, Y F, Sung, W F, Hahne, R A, Brown

Publikováno v: European journal of anaesthesiology. 17(1)

In a multicentre, randomized, double-blind, placebo-controlled dose-ranging study, 1030 patients undergoing outpatient surgery with general anaesthesia received i.v. dolasetron mesylate (12.5, 25, 50, or 100 mg) or placebo. The principal outcome meas

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::21ba9412de6814450a5f3d036ce13435
https://pubmed.ncbi.nlm.nih.gov/10758440

Zobrazit plný text záznamu

Single- and multiple-dose pharmacokinetics of oral dolasetron and its active metabolites in healthy volunteers: part 2

Autor: D C, Dimmitt, Y S, Choo, L A, Martin, T, Arumugham, W F, Hahne, S J, Weir

Publikováno v: Biopharmaceuticsdrug disposition. 20(1)

The single- and multiple-dose pharmacokinetics and dose-proportionality of oral dolasetron and its active metabolites over the therapeutic dose range was investigated in 18 healthy men. In an open-label, randomized, complete three-way crossover desig

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::218b60c482a2d4cc9ebc1fb8a8414729
https://pubmed.ncbi.nlm.nih.gov/10086836

Zobrazit plný text záznamu

Intravenous pharmacokinetics and absolute oral bioavailability of dolasetron in healthy volunteers: part 1

Autor: D C, Dimmitt, Y S, Choo, L A, Martin, T, Arumugham, W F, Hahne, S J, Weir

Publikováno v: Biopharmaceuticsdrug disposition. 20(1)

In this first part of a two-part investigation, the intravenous dose proportionality of dolasetron mesylate, a 5-HT3 receptor antagonist, and the absolute bioavailability of oral dolasetron mesylate were investigated. In an open-label, randomized, fo

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::7f28c7285b82797c8443b05deec33407
https://pubmed.ncbi.nlm.nih.gov/10086835

Zobrazit plný text záznamu

Rationale for the use of a single fixed intravenous dolasetron dose for the prevention of cisplatin-induced nausea and vomiting. Pooled analysis of 14 clinical trials

Autor: J B, Whitmore, M G, Kris, P J, Hesketh, T H, Grote, D M, DuBois, M B, Cramer, W F, Hahne

Publikováno v: Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer. 6(5)

Dolasetron mesilate is a selective 5-HT3 receptor antagonist that prevents chemotherapy-induced and postoperative nausea and vomiting. For the majority of patients in intravenous dolasetron trials for chemotherapy-induced nausea and vomiting, dosing

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::8f1b9574f2fac6da6ce8020a1771fbb6
https://pubmed.ncbi.nlm.nih.gov/9773466

Zobrazit plný text záznamu

Oral dolasetron mesylate for prevention of postoperative nausea and vomiting: a multicenter, double-blind, placebo-controlled study. The Oral Dolasetron PONV Prevention Study Group

Autor: P, Diemunsch, K, Korttila, J, Leeser, J H, Helmers, B, Wilkey, S, Navé, A J, Radke, W F, Hahne, R A, Brown

Publikováno v: Journal of clinical anesthesia. 10(2)

To examine the safety and effectiveness of a range of single oral doses of dolasetron mesylate for the prevention of postoperative nausea and vomiting.Randomized, double-blind, placebo-controlled trial.32 hospitals.789 female ASA physical status I, I

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::f2c1047ea8de453ad174df920f05148f
https://pubmed.ncbi.nlm.nih.gov/9524901

Zobrazit plný text záznamu

Treatment of postoperative nausea and vomiting with single intravenous doses of dolasetron mesylate: a multicenter trial. Dolasetron Mesylate PONV Treatment Study Group

Autor: A L, Kovac, P E, Scuderi, T F, Boerner, J E, Chelly, M E, Goldberg, C B, Hantler, W F, Hahne, R A, Brown

Publikováno v: Anesthesia and analgesia. 85(3)

This study was conducted to determine the efficacy and safety of four intravenous (I.V.) doses of dolasetron, an investigational 5-HT3 receptor antagonist, for the treatment of postoperative nausea and/or vomiting (PONV) after outpatient surgery unde

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::7f6dced9faaf1b55250917e6aa27da7a
https://pubmed.ncbi.nlm.nih.gov/9296407

Zobrazit plný text záznamu

Randomized, double blind, dose-response trial across four oral doses of dolasetron for the prevention of acute emesis after moderately emetogenic chemotherapy. Oral Dolasetron Dose-Response Study Group

Autor: E B, Rubenstein, R J, Gralla, J D, Hainsworth, P J, Hesketh, T H, Grote, M R, Modiano, A, Khojasteh, L A, Kalman, C R, Benedict, W F, Hahne

Publikováno v: Cancer. 79(6)

This double blind parallel group study assessed the acute antiemetic efficacy of four oral doses of dolasetron mesylate in cancer patients receiving their first course of intravenous chemotherapy with doxorubicin and/or cyclophosphamide.Patients were

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::1aeaee7b40eaaf93dd30b5d776932884
https://pubmed.ncbi.nlm.nih.gov/9070501

Zobrazit plný text záznamu

Oral dolasetron mesylate in patients receiving moderately emetogenic platinum-containing chemotherapy. Oral Dolasetron Dose Response Study Group

Autor: T H, Grote, L F, Pineda, R A, Figlin, K B, Pendergrass, P J, Hesketh, B Y, Karlan, J A, Reeves, L L, Porter, C R, Benedict, W F, Hahne

Publikováno v: The cancer journal from Scientific American. 3(1)

This double-blind, dose-response study was conducted to assess the safety and efficacy of four oral doses of dolasetron mesylate for preventing acute emesis in cancer patients receiving their first course of moderately emetogenic platinum-containing

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::d83eb57bb36988aaba64bbf439114623
https://pubmed.ncbi.nlm.nih.gov/9072308

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání